
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration has granted expanded approval to protease inhibitor Prezista for use in first-line therapy among treatment-naive HIVers as well as full approval for its use among treatment-experienced adults. Prezista previously was approved under an accelerated review program only for HIVers with drug resistance. --------------------- A study in the journal AIDS recommends several guidelines to monitor HIVers for emerging resistance to Prezista, including the development of two viral mutations conveying drug resistance and high viral loads after 24 weeks of treatment. Patients who've developed resistance to Prezista also should be monitored for possible cross-resistance to Aptivus, according to the study. --------------------- An analysis in the journal AIDS has shown that newer once-daily, fixed-dose antiretroviral regimens like Epzicom, Atripla, and Truvada are more durable than earlier antiretroviral drugs. Durability is vital to long-term treatment success since anti-HIV medications must be taken indefinitely. --------------------- Data from two long-term studies reported in the journal AIDS confirm the results of previous research that has shown that Viread can negatively affect kidney function, but they also show that kidney toxicity is generally mild and is not linked with the development of more serious renal disease. --------------------- The FDA has announced that it is investigating possible hemarthrosis, a side effect marked by bleeding into the body's joints, with the nonnuke Intelence. The agency also is investigating the hepatitis B treatment Tyzeka for possible peripheral neuropathy. --------------------- Myriad Genetics is launching Phase II human trials of experimental maturation inhibitor vivecon (MPC-9055). The drug, part of an entirely new class of antiretrovirals, targets one of the final stages of viral replication by interfering with the assembly of newly created HIV particles. --------------------- The FDA has made changes to the label of protease inhibitor Norvir to indicate that the drug might cause heart rhythm abnormalities. The label now says Norvir should be used with caution in patients with heart disease or preexisting cardiac abnormalities. --------------------- Merck has launched a study of integrase inhibitor Isentress for use in first-line therapy among treatment-naive HIVers. Isentress is currently approved only for patients with drug-resistant infections. --------------------- Studies of Tibotec experimental nonnuke rilpivirine (TMC278) have shown that the drug might offer months of sustained anti-HIV activity after a single injection of a 'depot formulation' that releases medication in the body slowly over time. Additional studies have been planned. --------------------- A study of the antiepileptic drug Lyrica (pregabalin) for the treatment of HIV-associated peripheral neuropathy has shown that the medication was only slightly more effective in reducing pain scores than a placebo. The medication has been shown to help with other neuropathic pain syndromes. --------------------- HIVers treated with interferon for hepatitis C coinfection could face higher risks for neuropsychiatric side effects if also taking Sustiva, researchers report in the Journal of Acquired Immune Deficiency Syndromes. Combining the two medications boosted reported mood disorders by 50%. --------------------- An analysis of Spanish HIVers has shown that risks for progressive multifocal leukoencephalopathy, a potentially severe brain infection, remain high even in the presence of successful antiretroviral treatment. Many of the 61 PML cases diagnosed occurred among HIVers with undetectable viral loads and CD4-cell counts above 200.
From our Sponsors
Most Popular
Why activist Raif Derrazi thinks his HIV diagnosis is a gift
September 17 2024 12:00 PM
Out100 Honoree Tony Valenzuela thanks queer and trans communities for support in his HIV journey
September 18 2024 12:00 PM
How fitness coach Tyriek Taylor reclaims his power from HIV with self-commitment
September 19 2024 12:00 PM
Creator and host Karl Schmid fights HIV stigma with knowledge
September 12 2024 12:03 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
Plus: Featured Video
Latest Stories
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
SFAF's Dr. Tyler TerMeer says he'll continue to fight for health care for all
January 28 2025 3:00 PM
Lexi Love goes public with HIV status after Trump wipes resources from federal website
January 23 2025 11:23 AM
Plus nominated for 2025 GLAAD Media Award alongside industry giants like Vogue, People, and Variety
January 22 2025 12:42 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM
Check out our 2024 year-end issue!
October 28 2024 2:08 PM
Meet our Health Hero of the Year, Armonté Butler
October 21 2024 12:53 PM
AIDS/LifeCycle is ending after more than 30 years
October 17 2024 12:40 PM
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
October 15 2024 5:03 PM
Kentucky bans conversion therapy for youth as Gov. Andy Beshear signs 'monumental' order
September 18 2024 11:13 AM
Study finds use of puberty blockers safe and reversible, countering anti-trans accusations
September 11 2024 1:11 PM
Latinx health tips / Consejos de salud para latinos (in English & en espanol)
September 10 2024 4:29 PM